MiR-101-3p inhibits the growth and metastasis of non-small cell lung cancer through blocking PI3K/AKT signal pathway by targeting MALAT-1.

[1]  H. Benyamini,et al.  Long Noncoding RNA MALAT1 Promotes Hepatocellular Carcinoma Development by SRSF1 Upregulation and mTOR Activation. , 2017, Cancer research.

[2]  Xinran Tang,et al.  MicroRNA-101 inhibits invasion and angiogenesis through targeting ITGA3 and its systemic delivery inhibits lung metastasis in nasopharyngeal carcinoma , 2017, Cell Death & Disease.

[3]  T. Song,et al.  MicroRNA-101 suppresses progression of lung cancer through the PTEN/AKT signaling pathway by targeting DNA methyltransferase 3A , 2016, Oncology letters.

[4]  Yusuke Nakamura,et al.  MEK inhibitors against MET-amplified non-small cell lung cancer , 2016, International journal of oncology.

[5]  Lei Wang,et al.  MiRNA-101 inhibits oral squamous-cell carcinoma growth and metastasis by targeting zinc finger E-box binding homeobox 1. , 2016, American journal of cancer research.

[6]  G. Calin,et al.  Genetic and epigenetic alterations of microRNAs and implications for human cancers and other diseases , 2016, Genes, chromosomes & cancer.

[7]  Zhongzhen Su,et al.  Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2 , 2016, Oncotarget.

[8]  M. Cañadas-Garre,et al.  PTEN and PI3K/AKT in non-small-cell lung cancer. , 2015, Pharmacogenomics.

[9]  Xiu-li Wang,et al.  MiRNA-101 inhibits breast cancer growth and metastasis by targeting CX chemokine receptor 7 , 2015, Oncotarget.

[10]  Peng Zhang,et al.  Micro ribonucleic acid (RNA)-101 inhibits cell proliferation and invasion of lung cancer by regulating cyclooxygenase-2 , 2015, Thoracic cancer.

[11]  Xuhui Zhou,et al.  MALAT1 promotes the proliferation and metastasis of osteosarcoma cells by activating the PI3K/Akt pathway , 2015, Tumor Biology.

[12]  Meng Li,et al.  Silencing of Long Noncoding RNA MALAT1 by miR-101 and miR-217 Inhibits Proliferation, Migration, and Invasion of Esophageal Squamous Cell Carcinoma Cells* , 2014, The Journal of Biological Chemistry.

[13]  L. Burzio,et al.  Down-regulation of the Antisense Mitochondrial Non-coding RNAs (ncRNAs) Is a Unique Vulnerability of Cancer Cells and a Potential Target for Cancer Therapy , 2014, The Journal of Biological Chemistry.

[14]  D. Spector,et al.  The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. , 2013, Cancer research.

[15]  Jianping Chen,et al.  Ophiopogonin B-induced autophagy in non-small cell lung cancer cells via inhibition of the PI3K/Akt signaling pathway , 2012, Oncology reports.

[16]  S. Koschmieder,et al.  The Long Noncoding MALAT-1 RNA Indicates a Poor Prognosis in Non-small Cell Lung Cancer and Induces Migration and Tumor Growth , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[17]  J. S. Rao,et al.  MMP‐2 alters VEGF expression via αVβ3 integrin‐mediated PI3K/AKT signaling in A549 lung cancer cells , 2009, International journal of cancer.

[18]  A. Yoshizawa,et al.  Overexpression of Phospho-eIF4E Is Associated with Survival through AKT Pathway in Non–Small Cell Lung Cancer , 2009, Clinical Cancer Research.

[19]  J. Flickinger,et al.  Factors associated with local and distant recurrence and survival in patients with resected nonsmall cell lung cancer , 2009, Cancer.

[20]  David V Schaffer,et al.  PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation , 2007, Developmental neurobiology.

[21]  K. Okkenhaug,et al.  PI3K in lymphocyte development, differentiation and activation , 2003, Nature Reviews Immunology.

[22]  Yuan Xue,et al.  Prognostic value of long noncoding RNA MALAT1 in various carcinomas: evidence from nine studies , 2015, Tumor Biology.

[23]  Jian-feng Dong,et al.  Interleukin-1β-mediated suppression of microRNA-101 and upregulation of enhancer of zeste homolog 2 is involved in particle-induced lung cancer , 2014, Medical Oncology.